Streetbeat News

Analyst Ratings

FUSN

Raymond James analyst Rahul Sarugaser has reaffirmed a Strong Buy rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and increased the price target from $15 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:30 pm

AGNC

RBC Capital analyst Kenneth Lee has maintained an Outperform rating on AGNC Investment (NASDAQ:AGNC) and increased the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 7:28 pm

AGL

DIA

KRE

MPW

NVDA

PBW

PTON

QQQ

SPY

U.S. stocks showed mixed performance on Friday, with the S&P 500 and Nasdaq 100 slightly up, while the Dow Jones and Russell 2000 saw declines. Strong jobs data suggested less likelihood of Federal Reserve rate cuts, but a disappointing ISM Service PMI led to lower Treasury yields and some support for stocks. Sector ETFs varied, with Communication Services up and Real Estate down. Regional banks rose, clean energy fell, and semiconductor stocks rebounded. Peloton surged on TikTok partnership news, Agilon Health plunged on reduced revenue guidance and a JPMorgan downgrade, and Medical Properties dropped after announcing plans to reduce exposure to a tenant.

Portfolio Pulse from Piero Cingari

January 05, 2024 | 7:13 pm

SNOW

Snowflake Inc (NYSE:SNOW) stock is trading higher after RBC Capital analyst Matthew Hedberg initiated coverage with an Outperform rating and a $230 price target. Hedberg is optimistic about Snowflake's long-term growth, citing improving cloud optimization trends, rapid adoption of Snowpark, and potential with new GenAI offerings. He believes Snowflake is well-positioned for cross-selling into ML and GenAI use cases and expects a more material impact on results in CY25 and beyond. The analyst also views management as best-in-class and projects Q4 revenue and EPS slightly above consensus.

Portfolio Pulse from Anusuya Lahiri

January 05, 2024 | 7:10 pm

NEM

Benzinga's options scanner revealed significant bullish options activity on Newmont (NYSE:NEM), with 55% bullish sentiment among 9 trades. The options indicate a targeted price range of $30.0 to $42.5. Newmont, the world's largest gold miner, recently acquired Newcrest and is expected to produce 7.3 million ounces of gold in 2023. The stock is slightly up with a potential overbought RSI indicator, and UBS maintains a Neutral rating with a $40 target price.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:01 pm

Tradeweb Markets (NASDAQ:TW) has been analyzed by 10 analysts in the last three months, with a diverse range of perspectives. The recent assessments show a shift towards a more bullish outlook, with the average 12-month price target raised to $96.5, up from the previous $90.10. Analysts from firms like Raymond James, UBS, Morgan Stanley, Rosenblatt, JP Morgan, Deutsche Bank, Barclays, and Piper Sandler have raised their price targets for TW, indicating a positive sentiment towards the company's performance and market position.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:01 pm

SHAK

Analyst ratings for Shake Shack (NYSE:SHAK) show a mix of opinions, with 9 analysts offering varied ratings over the last quarter. The 12-month price targets have an average of $71.11, with a high of $85.00 and a low of $59.00, reflecting a 1.51% decrease from the previous average. Recent actions include ratings and target adjustments by analysts from firms such as Oppenheimer, HSBC, Raymond James, Truist Securities, Stifel, Barclays, Deutsche Bank, and Morgan Stanley. Shake Shack's financials indicate a solid revenue growth rate of 21.24%, an exceptional net margin of 2.76%, but lower ROE and ROA compared to industry averages, and a healthy debt-to-equity ratio of 1.84.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm

CTRA

Seven analysts have recently updated their ratings on Coterra Energy (NYSE:CTRA), with an average 12-month price target of $31.29, up from $30.40. The ratings range from bullish to indifferent, with no bearish sentiments. Analysts from B of A Securities, Raymond James, UBS, Citigroup, Truist Securities, and Susquehanna have adjusted their price targets and ratings, reflecting their views on the company's performance and market conditions. Coterra, an independent exploration and production company, has faced a significant revenue decline of -46.19% over the past 3 months but maintains a strong net margin of 23.75%. However, its ROE and ROA are below industry averages, and it has a low debt-to-equity ratio of 0.2.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm

PCVX

PHAT

Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT), raising the price target to $26 from $23 and adding it to the Needham Conviction List. Phathom's stock is expected to perform strongly in 2024 due to the launch of Voquezna in Erosive GERD and its anticipated approval and launch in Non-Erosive GERD (NERD). The analyst projects $55.6 million in Voquezna sales for 2024, which is above the consensus estimate of $46 million. Voquezna is seen as a potential best-in-class acid blocker with significant peak sales potential in various indications. Phathom's cash runway is expected to last through 2026, covering multiple value-driving events. PHAT shares recently traded slightly lower at $8.98.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 6:52 pm

TRDA

Entrada Therapeutics' stock price has risen following Oppenheimer's initiation of coverage with an Outperform rating and a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 6:51 pm